Literature DB >> 9278190

A two-process theory of schizophrenia: evidence from studies in post-mortem brain.

J F Deakin1, M D Simpson.   

Abstract

Glutamate and GABA are the principle neurotransmitters of the cerebral cortex and are known to modulate dopaminergic function. Evidence of structural abnormalities in the cortex raises the possibility that schizophrenia involves disturbances of cortical amino-acid neurotransmission. The psychotomimetic effects of phencyclidine, a glutamate antagonist, have been taken to suggest that schizophrenia involves reduced brain glutamate function. Direct evidence for diminished glutamate function in schizophrenia is lacking. However, in polar temporal cortex and hippocampus we reported evidence of an asymmetric loss of glutamate terminals, and of reduced GABA function, which may be secondary to the loss of glutamatergic input. Glutamate cell body markers are spared in temporal lobe; the neurones which degenerate may originate in frontal cortex. A number of studies have reported increases in markers of glutamatergic cell bodies and terminals in orbital frontal cortex in schizophrenia. These findings are consistent with the presence of an abnormally abundant glutamatergic innervation, which may be the result of an arrest in the normal process of cellular and synaptic elimination which occurs during development. There is evidence that frontal abnormalities in schizophrenia are genetically determined. We suggest that glutamatergic abnormalities in anterior temporal cortex in schizophrenia are the result of the degeneration of fronto-temporal projections. Orbital frontal projections to polar temporal cortex may be prone to degeneration because they arise from an unstable frontal cortical cytoarchitecture which has not completed the normal process of post-natal remodelling. The structural abnormality of the orbital frontal region may confer vulnerability to some intrinsic or extrinsic mechanism, which brings about a progressive degeneration of projections to polar temporal lobe.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9278190     DOI: 10.1016/s0022-3956(96)00042-8

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  20 in total

1.  Uncinate fasciculus findings in schizophrenia: a magnetic resonance diffusion tensor imaging study.

Authors:  Marek Kubicki; Carl-Fredrik Westin; Stephan E Maier; Melissa Frumin; Paul G Nestor; Dean F Salisbury; Ron Kikinis; Ferenc A Jolesz; Robert W McCarley; Martha E Shenton
Journal:  Am J Psychiatry       Date:  2002-05       Impact factor: 18.112

Review 2.  Animal models of schizophrenia: a critical review.

Authors:  E R Marcotte; D M Pearson; L K Srivastava
Journal:  J Psychiatry Neurosci       Date:  2001-11       Impact factor: 6.186

Review 3.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

4.  Fronto-temporal disconnectivity in schizotypal personality disorder: a diffusion tensor imaging study.

Authors:  Motoaki Nakamura; Robert W McCarley; Marek Kubicki; Chandlee C Dickey; Margaret A Niznikiewicz; Martina M Voglmaier; Larry J Seidman; Stephan E Maier; Carl-Fredrik Westin; Ron Kikinis; Martha E Shenton
Journal:  Biol Psychiatry       Date:  2005-06-22       Impact factor: 13.382

Review 5.  Glutamate dysfunction in hippocampus: relevance of dentate gyrus and CA3 signaling.

Authors:  Carol A Tamminga; Sarah Southcott; Carolyn Sacco; Anthony D Wagner; Subroto Ghose
Journal:  Schizophr Bull       Date:  2012-04-24       Impact factor: 9.306

6.  Proteomics as a tool for understanding schizophrenia.

Authors:  Daniel Martins-de-Souza
Journal:  Clin Psychopharmacol Neurosci       Date:  2011-12-31       Impact factor: 2.582

7.  Microstructural abnormalities of uncinate fasciculus as a function of impaired cognition in schizophrenia: A DTI study.

Authors:  Sadhana Singh; Kavita Singh; Richa Trivedi; Satnam Goyal; Prabhjot Kaur; Namita Singh; Triptish Bhatia; Smita N Deshpande; Subash Khushu
Journal:  J Biosci       Date:  2016-09       Impact factor: 1.826

Review 8.  The potential role of lamotrigine in schizophrenia.

Authors:  Charles H Large; Elizabeth L Webster; Donald C Goff
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

9.  Right-hemisphere encephalopathy in elderly subjects with schizophrenia: evidence from neuropsychological and brain imaging studies.

Authors:  V S Gabrovska-Johnson; M Scott; S Jeffries; N Thacker; R C Baldwin; A Burns; S W Lewis; J F W Deakin
Journal:  Psychopharmacology (Berl)       Date:  2003-07-04       Impact factor: 4.530

10.  White matter hemisphere asymmetries in healthy subjects and in schizophrenia: a diffusion tensor MRI study.

Authors:  Hae-Jeong Park; Carl-Fredrik Westin; Marek Kubicki; Stephan E Maier; Margaret Niznikiewicz; Aaron Baer; Melissa Frumin; Ron Kikinis; Ferenc A Jolesz; Robert W McCarley; Martha E Shenton
Journal:  Neuroimage       Date:  2004-09       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.